Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
نویسندگان
چکیده
1. O’Rand MG, Widgren EE, Fisher SJ. Characterization of the rabbit sperm membrane autoantigen, RSA, as a lectin-like zona binding protein. Dev Biol. 1988;129:231-240. 2. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001;97:1508-1510. 3. Chiriva-Internati M, Wang Z, Salati E, Timmins P, Lim SH. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer. 2002;94:2447-2453. 4. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol. 2002;56:429-433. 5. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002;100:961-965.
منابع مشابه
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
The traditional approach to therapy for previously untreated patients with chronic lymphocytic leukemia (CLL) has been chemoimmunotherapy programs (whether FCR [fludarabine, cyclophosphamide, rituximab], FR [fludarabine, rituximab], BR [bendamustine, rituximab], PCR [pentostatin, cyclophosphamide, rituximab], other. These combination treatments have led to increased rates of clinical remission,...
متن کامل[Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
OBJECTIVES We evaluated the cost-effectiveness of rituximab added to the chemotherapy regimen of fludarabine plus cyclophosphamide (R-FC) versus fludarabine plus cyclophosphamide (FC) for the treatment of patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). METHODS Two Markov models were built, using published results on progression-free survival (PFS)...
متن کاملThe case for rituximab in AIDS-related lymphoma.
not show significant differences in early infection risk compared with those recorded in the preceding (non–rituximab-containing) regimens. Similarly, in randomized prospective comparisons of fludarabine versus F-R, 6 fludarabine, cyclophosphamide and mitoxantrone (FCM) versus FCM-rituximab, 7 and fludarabine, mitoxantrone, dexamethasone (FND) versus FND-rituximab, 8 no excess in early infectio...
متن کاملTreatment of fludarabine-refractory chronic lymphocytic leukemia.
The development of resistance to purine analogs defines a poor-risk subset of patients with chronic lymphocytic leukemia (CLL). Although in recent years chemoimmunotherapeutic combinations such as fludarabine, cyclophosphamide, and rituximab have induced response rates of 95% in previously untreated patients and increased the rates of failure-free survival, CLL remains incurable for many patien...
متن کاملNew developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent cellular cytotoxicity and direct cell death, leading to superior cytotoxicity compared with rituximab. The approval of obinutuzumab by US Food and Drug Administration was based on a pivotal, phase III, randomized trial of chlorambucil monotherapy (n=...
متن کاملNovel treatment for congenital FXIII deficiency.
light of the results of the French study, one can only agree with the recommendation of Lepretre et al that FCA should not be used for the treatment of CLL outside of clinical trials. The question of whether alemtuzumab should no longer be used in any chemoimmu-notherapy is an entirely different issue. It should be emphasized that a recent random-ized trial showed that the second-line use of fl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 102 6 شماره
صفحات -
تاریخ انتشار 2003